Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis

被引：67

作者：

Vener, Claudia ^{[1
]}

Fracchiolla, Nicola Stefano ^{[1
]}

Gianelli, Umberto ^{[2
]}

Calori, Rossella ^{[1
]}

Radaelli, Franca ^{[3
]}

Iurlo, Alessandra ^{[3
]}

Caberlon, Sabrina ^{[4
]}

Gerli, Giancarla ^{[4
]}

Boiocchi, Leonardo ^{[2
]}

Deliliers, Giorgio Lambertenghi ^{[1
]}

机构：

[1] Univ Milan, IRCCS, Osped Maggiore Policlin Mangiagalli & Regina Elen, Milan, Italy

[2] Univ Milan, Dipartimento Med Chirurgia, II Cattedra Anat Patol, E Odontoiatria DMCO IRCCS, Milan, Italy

[3] IRCCS Osped Maggiore Policlin Mangiagali & Regina, Div Ematol, Milan, Italy

[4] Univ Milan, DMCO, Unita Ematol & Trombosi, Milan, Italy

来源：

BLOOD | 2008年 / 111卷 / 04期

关键词：

D O I：

10.1182/blood-2007-09-112953

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Various clinical prognostic scoring systems (PSSs) have been suggested as means of selecting high-risk chronic idiopathic myelofibrosis (CIMF) patients at diagnosis. The WHO has recently proposed strict diagnostic criteria for CIMF, and the European consensus for bone marrow fibrosis (BMF) grading recommends 4 classes. It has been suggested that BMF grading may play a prognostic role in CIMF, but it has never been compared with the other PSSs in the same patients. We tested a prognostic model for overall survival (OS) based on the WHO criteria and BMF grading in 113 consecutive patients with chronic myeloproliferative disorders (98 with CIMF and 15 with postpolycythemic myelofibrosis), and compared the findings with those of PSSs. The results showed that our model is significantly associated with different OSs and, unlike the other PSSs, clearly discriminates the OS of intermediate- and high-risk patients.

引用

页码：1862 / 1865

页数：4

共 18 条

[1] Myelofibrosis with myeloid metaplasia: Diagnostic definition and prognostic classification for clinical studies and treatment guidelines [J].